Financial & competing interests disclosure
M Mockenhaupt is the coordinator of the international RegiSCAR-project, which was/is funded by grants from the European Commission (QLRT-2002-01738), GIS-Institut des Maladies Rares and INSERM (4CH09G) in France and by a consortium of pharmaceutical companies (Bayer Vital, Berlin-Chemie, Boehringer-Ingelheim, Cephalon, GlaxoSmithKline, Grünenthal, MSD Sharp & Dohme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier and Tibotec). M Mockenhaupt received the Else Kröner Memorial Stipendium for support of clinical research through the Else Kröner-Fresenius Foundation. She has been an expert in litigations concerning SJS/TEN and has served on expert panels and advisory boards coordinated by pharmaceutical companies. Currently, RegiSCAR Germany receives funding by the Ministry for Education and Research (Bundesministerium für Bildung und Forschung [BMBF]; grant no. 01KG1018). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.